Since 2017, three TAP-supported therapies have been approved by the U.S. Food and Drug Administration (FDA):

• CPX-351 (Vyxeos^®), first approved treatment (an innovative reformulation of two chemotherapies) for patients with certain types of high-risk acute myeloid leukemia (AML) - approved on August 3 2017 with clinical data published in J Clin Oncol
• Axicabtagene ciloleucel (Yescarta^®), first CAR T-cell immunotherapy approved for patients with non-Hodgkin lymphoma (NHL) and transformed follicular lymphoma (tFL) - approved on October 18 2017 with clinical data published in Lancet Oncol
• Tagraxofusp-erzs (Elzonris^®), first approved therapy for children and adults with blastic plasmacytoid dendritic cell neoplasm (BPDCN) - approved on December 21 2018 with clinical data published in N Engl J Med

Currently, there are over 20 TAP-supported companies or institutions with assets in active development, including 5 ongoing or planned registration-enabling clinical studies.

TAP Portfolio Assets in Company Sponsored Trials - Blood Cancer Development